



Press communication

Lund, Sweden, 1 September 2022

This is a translation of the Swedish press release published 2022-09-01

Clinical Manager recruited – Neola Medical strengthens the team with a neonatologist

Neola Medical AB (publ) announces that PhD MD Tetiana Kovtiukh has been recruited as Clinical Manager, starting her full-time position in September 2022. Tetiana will ensure clinical compatibility in product development and regulatory processes and build a clinical network for the company. Tetiana Kovtiukh is a neonatologist and worked most recently at Taras Shevchenko National University of Kyiv, Ukraine, teaching international students at the department for clinical medicine, and have previously also worked as a medical advisor at AbbVie and Teva.

“Since we are in the process for regulatory approvals in the EU and the U.S., and are preparing for market launch, I am happy that we have strengthened the team with an experienced doctor in neonatology, who also have experience from the industry. It is rare to have the combined experience from both the clinical and the industry side, and this will be highly valuable for our company.”, says Hanna Sjöström, CEO at Neola Medical.

PhD MD Tetiana Kovtiukh was recruited by Neola Medical soon after the outbreak of the war in the Ukraine. She started working at Neola Medical in March 2022 and will start her full-time position as Clinical Manager in September 2022. Tetiana adds valuable knowledge within neonatology and clinical competence to the company. Tetiana has 10 years of experience from neonatology, and she has a PhD in neonatology from National Medical University, Ukraine. She has previously worked at Taras Shevchenko National University of Kyiv, Ukraine, where she was teaching international students at the department for clinical medicine. She also worked as a medical advisor within the international companies AbbVie and Teva, providing scientific support and expertise regarding products utilized in neonatal intensive care, for instance surfactant.

“I arrived in Sweden in March 2022 together with my son, as I soon after the outbreak of the war got this fantastic work opportunity at Neola Medical. I am happy to be working with Neola®, since the product has a direct link to my background as a doctor within neonatology, and I see great possibilities to upgrade today’s care of preterm born infants with this technology”, says Tetiana Kovtiukh, Clinical Manager at Neola Medical.

The recruitment of Tetiana Kovtiukh is the company’s third key recruitment during 2022 that further strengthens the team with clinical knowledge, valuable in applications for granted market approval in the EU and the U.S. Earlier this year, Cecilia Larsson was recruited as Regulator Affairs Manager and Magnus Johnsson as Director Quality Assurance & Regulatory Affairs.

Neola®

Neola Medicals product Neola® is a medical device for continuous and non-invasive lung monitoring of premature babies. The system measures changes in lung volume and oxygen concentration in the lungs of premature infants with the possibility of immediately detecting pulmonary conditions such as atelectasis, pneumothorax, a blocked airway, or a misplaced tracheal tube. This means that healthcare professionals can detect complications in real time and treat patients directly.

For further information, contact:

Hanna Sjöström, CEO Neola Medical, tel: 0760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com

Neola Medical AB (publ) develops technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporex AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more on www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB, tel: +46 (0)8-528 00 399, e-mail: info@fnca.se